Abstract
Fingolimod (FING) is the first oral immunomodulatory treatment approved for the 2-line disease-modifying treatment of active relapsing-remitting (RR) forms of multiple sclerosis (MS). Observational post-marketing studies are important for clarifying the efficacy and safety of the product in current medical practice. The Aim of our study is to assess the effectiveness of FING in patients with RR-MS followed at the National institution of neurology in Tunis.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
